MenB vaccine offers men no protection from gonorrhoea, claims major study
The Meningitis B vaccine does not prevent gonorrhoea infections despite being offered to at-risk men, scientists say. The NHS started offering the vaccine to men who have sex with men last year, afte
The Meningitis B vaccine does not prevent gonorrhoea infections despite being offered to at-risk men, scientists say. The NHS started offering the va
Read Full Story at BBC Health →Why This Matters
The revelation that the MenB vaccine offers no protection against gonorrhoea underscores a critical gap in public health strategy. For high-risk groups like men who have sex with men, this exposes the limitations of relying on existing vaccines for sexually transmitted infections. The finding also raises questions about the broader efficacy of vaccination programs when targeted at specific infections rather than broader pathogen families.
Background Context
The MenB vaccine was introduced in the UK primarily to combat invasive meningococcal disease, a life-threatening condition most common in infants and young adults. Its repurposing for at-risk men last year was a pragmatic step given the vaccine's safety profile and limited alternatives for gonorrhoea prevention. However, the genetic and bacterial differences between *Neisseria meningitidis* and *Neisseria gonorrhoeae* may have made such cross-protection implausible from the outset.
What Happens Next
Public health authorities will need to reassess their reliance on MenB for gonorrhoea prevention, likely accelerating investment in dedicated STI vaccines or alternative prevention methods. Clinicians may face pressure to advise at-risk patients to pair existing protections with condom use or regular testing. Meanwhile, researchers will scrutinize whether the vaccine's failure in this context signals broader challenges for bacterial vaccines targeting similar pathogens.
Bigger Picture
This development fits a growing pattern where vaccines designed for one pathogen show limited or no efficacy against genetically related but clinically distinct organisms. It also highlights the fragmented approach to STI prevention, where failures in one area can outpace progress in others. As antibiotic resistance in gonorrhoea rises, the search for reliable prevention tools becomes even more urgent—and this study serves as a reminder that innovation in vaccines remains uneven.
